Lavipharm Statistics

Total Valuation

Lavipharm has a market cap or net worth of EUR 131.24 million. The enterprise value is 159.57 million.

Market Cap	131.24M
Enterprise Value	159.57M

Important Dates

The next estimated earnings date is Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Lavipharm has 168.69 million shares outstanding. The number of shares has increased by 0.17% in one year.

Current Share Class	n/a
Shares Outstanding	168.69M
Shares Change (YoY)	+0.17%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	3.39%
Float	64.01M

Valuation Ratios

The trailing PE ratio is 15.14.

PE Ratio	15.14
Forward PE	n/a
PS Ratio	2.48
PB Ratio	2.48
P/TBV Ratio	16.84
P/FCF Ratio	n/a
P/OCF Ratio	28.28
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.25, with an EV/FCF ratio of -31.89.

EV / Earnings	17.77
EV / Sales	3.01
EV / EBITDA	16.25
EV / EBIT	30.45
EV / FCF	-31.89

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.64.

Current Ratio	1.15
Quick Ratio	0.56
Debt / Equity	0.64
Debt / EBITDA	3.45
Debt / FCF	-6.78
Interest Coverage	2.61

Financial Efficiency

Return on equity (ROE) is 18.10% and return on invested capital (ROIC) is 4.04%.

Return on Equity (ROE)	18.10%
Return on Assets (ROA)	2.73%
Return on Invested Capital (ROIC)	4.04%
Return on Capital Employed (ROCE)	6.07%
Revenue Per Employee	177,077
Profits Per Employee	30,040
Employee Count	299
Asset Turnover	0.44
Inventory Turnover	1.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.15% in the last 52 weeks. The beta is 1.22, so Lavipharm's price volatility has been higher than the market average.

Beta (5Y)	1.22
52-Week Price Change	-8.15%
50-Day Moving Average	0.80
200-Day Moving Average	0.80
Relative Strength Index (RSI)	50.17
Average Volume (20 Days)	151,043

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lavipharm had revenue of EUR 52.95 million and earned 8.98 million in profits. Earnings per share was 0.05.

Revenue	52.95M
Gross Profit	25.08M
Operating Income	5.24M
Pretax Income	3.60M
Net Income	8.98M
EBITDA	9.07M
EBIT	5.24M
Earnings Per Share (EPS)	0.05

Full Income Statement

Balance Sheet

The company has 5.59 million in cash and 33.92 million in debt, giving a net cash position of -28.34 million or -0.17 per share.

Cash & Cash Equivalents	5.59M
Total Debt	33.92M
Net Cash	-28.34M
Net Cash Per Share	-0.17
Equity (Book Value)	52.97M
Book Value Per Share	0.31
Working Capital	5.88M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.64 million and capital expenditures -9.64 million, giving a free cash flow of -5.00 million.

Operating Cash Flow	4.64M
Capital Expenditures	-9.64M
Free Cash Flow	-5.00M
FCF Per Share	-0.03

Full Cash Flow Statement

Margins

Gross margin is 47.37%, with operating and profit margins of 9.90% and 16.96%.

Gross Margin	47.37%
Operating Margin	9.90%
Pretax Margin	6.81%
Profit Margin	16.96%
EBITDA Margin	17.13%
EBIT Margin	9.90%
FCF Margin	n/a

Dividends & Yields

Lavipharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.17%
Shareholder Yield	-0.17%
Earnings Yield	6.84%
FCF Yield	-3.81%

Stock Splits

The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.

Last Split Date	Aug 1, 2022
Split Type	Reverse
Split Ratio	0.3333333333

Scores

Lavipharm has an Altman Z-Score of 1.55. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.55
Piotroski F-Score	n/a